Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
about
ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathyShould a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies.Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies.The year in cardiology 2015: acute coronary syndromes.New directions for pharmacotherapy in the treatment of acute coronary syndrome.Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.Dual antiplatelet therapy after coronary stenting.Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.Dual antiplatelet therapy for secondary prevention of coronary artery disease.Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma.Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches.Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper.Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma.[Secondary prevention after myocardial infarction with prolonged dual anti-platelet therapy (DAPT). A new therapeutic concept].Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery DiseasePractical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSGLS-409, an Antagonist of Both P2Y and P2Y, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation
P2860
Q33647497-18E4CC59-90D1-455F-A47B-F7802422F60BQ36117653-F4B02BB9-C197-477A-954C-B1189F865A31Q38379410-41D6019E-0BC8-4299-8F28-B3548C4A8AC3Q38635747-8718EE42-25D4-48D0-8CE5-ED2B098FEA25Q38685680-AF1BF2F7-CDFE-499A-8216-7E2E7F44E743Q38817144-50057DCE-3786-4653-9989-AF0297EC2907Q38859458-20597982-FEBD-4F0B-BB53-D672F7497AD6Q38866836-870A200D-4427-4EB3-955B-6A227619168AQ38869502-837BD81F-13A2-44F5-9317-56CFF5E31FAFQ38974884-DC849910-C2E7-4B32-BE0C-9ABFC2A4D069Q39093174-721504BB-DFA2-4BAD-A7D8-6372C3CBEF2CQ42650020-B6FA686A-A992-4792-82F2-37D8EF230B25Q47624810-51294CA4-BC17-4F4E-8AB1-8015F0D3E6ACQ48639751-4FED2652-A1FE-4E87-8CD7-D2B62AE67B07Q48761175-589928F5-245B-496B-851E-4EFD5BBA1480Q48761201-7723079A-6733-4682-B576-77EC9E4917FAQ49088428-0B17BAB8-2455-47A5-A894-95DD6D78C3EAQ49908641-84C01B83-3857-4D63-ABC1-625A0894AFD9Q49960669-9A756C11-9D1C-4A2F-B434-A7E54471EB2AQ50089557-45B01200-966F-4300-BFF8-E6A84FD1086EQ52593614-37343491-02A8-429F-9D47-9106693EC7B4Q53418383-32FD7851-F891-4D0E-A511-F95C9BA194CDQ56384060-895A682A-2BC9-451B-909C-230AF52D0659Q57154436-FB9F2951-8D87-41CF-9D0A-94FAA27BC16BQ57621041-0F82B963-2AD2-4CCA-849A-BF1422C2FB18Q59126251-37B54244-0BC9-43A4-8BCA-9906954B0732
P2860
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ischaemic risk and efficacy of ...... insights from PEGASUS-TIMI 54.
@en
type
label
Ischaemic risk and efficacy of ...... insights from PEGASUS-TIMI 54.
@en
prefLabel
Ischaemic risk and efficacy of ...... insights from PEGASUS-TIMI 54.
@en
P2093
P2860
P50
P356
P1476
Ischaemic risk and efficacy of ...... insights from PEGASUS-TIMI 54.
@en
P2093
Andrej Budaj
Anthony Dalby
Deepak L Bhatt
Diego Ardissino
Eva C Jensen
Frans Van de Werf
Giulia Magnani
José López-Sendón
Kyungah Im
Marc Cohen
P2860
P304
P356
10.1093/EURHEARTJ/EHV531
P577
2015-10-21T00:00:00Z